This inventor holds 9 USPTO granted patents and 2 published patent applications. Top assignees: Chemokine Therapeutics Corporation, Terragen Discovery Inc., The University of British Columbia. Active years: 2000-2008.
Company Filing History:
5 out of 7 
2 out of 3 
2 out of 959 
Years Active: 2000-2008
Title: Geeta Saxena: Innovator in Hematopoietic Cell Treatments
Introduction
Geeta Saxena is a prominent inventor based in Vancouver, Canada. She has made significant contributions to the field of hematopoietic cell treatments, holding a total of nine patents. Her work focuses on the therapeutic applications of CXCR4 antagonists and agonists, which have the potential to revolutionize treatments for various medical conditions.
Latest Patents
One of her latest patents involves the use of CXCR4 antagonists for the treatment of hematopoietic cells. This invention outlines how these antagonists can promote cellular multiplication, self-renewal, and proliferation of progenitor or stem cells. Additionally, she has developed methods for using CXCR4 agonists, including SDF-1 polypeptides, to reduce the rate of hematopoietic cell multiplication. These methods can be applied in vitro or in vivo, providing therapeutic options for patients requiring bone marrow or peripheral blood stem cell transplantation.
Career Highlights
Geeta Saxena has worked with notable organizations such as Chemokine Therapeutics Corporation and the University of British Columbia. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community significantly.
Collaborations
Throughout her career, Geeta has collaborated with esteemed colleagues, including Christopher R. Tudan and Hassan Salari. These partnerships have fostered innovation and have been instrumental in her research endeavors.
Conclusion
Geeta Saxena's work in the field of hematopoietic cell treatments showcases her dedication to advancing medical science. Her innovative patents and collaborations highlight her impact on the industry and her commitment to improving patient outcomes.